Related Experiment Video
Updated: Mar 6, 2026

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
Published on: February 21, 2018
Multiple MYO18A-PDGFRB fusion transcripts in a myeloproliferative neoplasm patient with t(5;17)(q32;q11)
Guangying Sheng1, Zhao Zeng1, Jinlan Pan1
1Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, the First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, Jiangsu province 215006 China.
Background:
Myeloproliferative neoplasms (MPNs), typically defined by myeloid proliferation and eosinophilia, and are only rarely caused by platelet-derived growth factor receptor beta (PDGFRB) gene rearrangements.
Case Presentation:
Here, we report a unique case of MPN that is negative for eosinophilia and characterized by a novel PDGFRB rearrangement. After cytogenetic analysis revealed a karyotype of t(5;17) (q32;q11), we used fluorescence in situ hybridization to specifically identify the PDGFRB gene at 5q31-q33 as the gene that had been translocated. Subsequently, RNA sequencing identified a new MYO18A-PDGFRB gene fusion. This fusion presented a previously undescribed breakpoint composed of exon 37 of MYO18A and exon 13 of PDGFRB. Furthermore, both RT-PCR and Bi-directional Sanger sequencing confirmed this out-of-frame fusion. Interestingly, we simultaneously identified the presence of another three PDGFRB transcripts, all of which were in-frame fusions. After treating the patient with imatinib, the t(5;17) translocation was no longer detected by conventional cytogenetics or by FISH, and at the time of the last follow-up, the patient had been in complete remission for 26 months.
Conclusion:
We prove that MYO18A-PDGFRB fusions are recurrent genetic aberrations involved in MPNs, and identify multiple fusion transcripts with novel breakpoints.
Insights
A novel MYO18A-PDGFRB gene fusion was identified in a patient with myeloproliferative neoplasms (MPNs) lacking eosinophilia. Treatment with imatinib led to complete remission, suggesting this fusion is a targetable aberration in MPNs.
Area of Science:
- Hematology
- Molecular Biology
- Genetics
Background:
- Myeloproliferative neoplasms (MPNs) are characterized by myeloid proliferation, but rarely involve platelet-derived growth factor receptor beta (PDGFRB) rearrangements.
- Eosinophilia is a common feature of MPNs, but its absence does not exclude the disease.
Observation:
- A unique MPN case lacking eosinophilia presented with a novel PDGFRB rearrangement, specifically a t(5;17) translocation.
- Fluorescence in situ hybridization (FISH) confirmed PDGFRB gene translocation to 5q31-q33.
- RNA sequencing identified a previously undescribed MYO18A-PDGFRB gene fusion with a novel breakpoint (exon 37 of MYO18A and exon 13 of PDGFRB).
Findings:
- RT-PCR and Sanger sequencing confirmed the out-of-frame MYO18A-PDGFRB fusion.
- Multiple in-frame PDGFRB fusion transcripts were also identified.
- Post-imatinib treatment, the t(5;17) translocation was undetectable by cytogenetics and FISH.
Implications:
- The MYO18A-PDGFRB fusion represents a recurrent genetic aberration in MPNs.
- Novel breakpoints in PDGFRB fusions expand our understanding of MPN pathogenesis.
- Targeting the MYO18A-PDGFRB fusion with imatinib induced complete remission, highlighting its therapeutic potential in specific MPN subtypes.
More Related Videos
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
Related Concept Videos
Abnormal Proliferation
Differentiation of Common Myeloid Progenitor Cells